ASH 2010 News Coverage

ASH 2010

Continuous Lenalidomide Regimen in Patients ≥65 Years With Newly Diagnosed Multiple Myeloma Resulted in “Unprecedented” Reduction in Risk of Disease Progression

Continuous lenalidomide treatment (MPR-R: melphalan, prednisone, and lenalidomide induction followed by lenalidomide maintenance) achieved a higher overall response rate (ORR) as well as better quality and more rapid responses than melphalan and prednisone (MP) in transplant-ineligible patients with newly diagnosed multiple myeloma. The data was presented at the 52nd American Society of Hematology Annual Meeting and Exposition.

Poor Prognosis Patients Newly Diagnosed With Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML) Show Response to Treatment With 5-Azacitidine + Vorinostat

The combination of 5-azacitidine and vorinostat is safe and active in patients with newly diagnosed myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) ineligible for clinical trials because of poor performance status or the presence of other comorbidities, results of an ongoing study presented at the 52nd American Society of Hematology Annual Meeting and Exposition have found.

Phase 2 Study of the JAK2 Inhibitor, INCB018424, in Patients With Refractory Leukemias Including Post-Myeloproliferative Disorder (MPD) Acute Myeloid Leukemia (sAML)

Alireza Eghtedar, MD, of the University of Texas in Houston, Texas, and colleagues conducted a study to evaluate the activity of INCB018424 in patients with advanced hematologic cancers and recently presented their findings at the 52nd American Society of Hematology Meeting and Exposition.

Sorafenib in Combination With Standard Induction and Consolidation Therapy in Elderly AML Patients: Results From a Randomized, Placebo-Controlled Phase 2 Trial

Hubert Serve of the Goethe University of Frankfurt in Frankfurt, Germany, and colleagues conducted a multicenter, randomized, placebo-controlled, double-blind, phase 2 trial in elderly (>60 years) AML patients to evaluate the effect of sorafenib in combination with standard chemotherapy and as a maintenance therapy for up to 1 year. The findings from this study were presented at the 52nd American Society of Hematology Meeting and Exposition.

Including Imatinib in Initial Therapy of Adults With Philadelphia-positive Acute Lymphoblastic Leukemia Significantly Enhances Long-Term Outcomes

Imatinib should be included in initial therapy of adult patients with Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL), final results of the largest single study of patients with Ph+ ALL have found. The study was presented at the 52nd American Society of Hematology Annual Meeting and Exposition.

Patients with Polycythemia Vera, Essential Thrombocythemia Refractory or Intolerant to Hydroxyurea Benefit From Treatment With the Kinase Inhibitor INCB018424

In patients with polycythemia vera (PV) and essential thrombocythemia (ET) refractory or intolerant to hydroxyurea, use of the JAK1/JAK2 inhibitor, INCB018424, results in rapid and durable clinical benefits, including normalization of hematologic parameters, resolution of splenomegaly, and alleviation of symptoms, long-term follow-up data from an ongoing open-label phase 2 study have found. The data was presented at the 52nd American Society of Hematology Annual Meeting and Exposition.

Decitabine Found to Be Safe, Effective in Patients With Myelodysplastic Syndrome Failing Prior Intensive Regimen

Patients with myelodysplastic syndrome (MDS) previously treated with intensive regimens had responses to decitabine similar to those who were treatment-naïve, suggesting this population should be considered for this hypomethylating therapy, results of a retrospective analysis have found. The data was presented at the 52nd American Society of Hematology Annual Meeting and Exposition.

Bosutinib or Imatinib Safe, Effective in Patients With Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia

A high combined percentage of newly diagnosed patients with Philadelphia chromosome-positive (Ph+) chronic phase (CP) chronic myeloid leukemia (CML) treated with bosutinib or imatinib achieve major molecular response (MMR), complete cytogenetic response (CCyR), and complete hematologic response (CHR), with a relatively low incidence of generally manageable grade 3 events, results of a randomized, open label, phase 3 study presented at the 52nd American Society of Hematology Annual Meeting and Exposition have found.

Follow-Up Results Support Potential Use of Dasatinib As Initial Therapy for Patients Newly Diagnosed With Chronic-Phase Chronic Myeloid Leukemia

Dasatinib continues to demonstrate superior efficacy compared with imatinib as initial treatment for patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP), results of an 18-month follow-up of the phase 3 DASISION comparative trial have shown. The data was presented at the 52nd American Society of Hematology Annual Meeting and Exposition.